Table 2 Safety and efficacy^a outcomes

Adverse events

7

7

1

 Serious adverse events

1

0

 Infections^b

2

4

 Pruritus

2

0

 Lower extremity edema

0

1

 Headache

1

0

 Dry mouth

0

1

 Nausea

0

1

 Fever

1

0

Absolute change in mRSS, abatacept

−8.6 ± 7.5

–

0.0625

Absolute change in mRSS, placebo

–

−2.3 ± 15

0.75

Change in HAQ-DI

−0.04 ± 0.24

0.25 ± 0.25

0.16

Change in physician global VAS

−11.9 ± 18.1

−17.3 ± 23.2

0.048

Change in patient global VAS

−8 ± 7.6

−2.7 ± 6.7

0.023

Change in patient pain VAS

−11.4 ± 8.3

−15 ± 25.1

0.18

Change in ESR

−6 ± 7.0

1.7 ± 7.6

0.37

Change in FVC % predicted

1.3 ± 8.5

0.3 ± 8.5

0.72

Change in DLCO % predicted

2.0 ± 6.3

−7.4 ± 10.7

0.84